Discovery calls for Series B companies: scaling without breaking for healthcare and life sciences
How Series B companies scale discovery calls across regions and teams without losing the discipline that made it work at Series A. Written for commercial leaders at healthtech, medtech, and life-sciences companies.
This edition is written for commercial leaders at healthtech, medtech, and life-sciences companies. In healthcare and life sciences, healthcare buyers move under regulatory constraint and reward domain-specific messaging, so the way you install discovery calls has to reflect that reality from day one.
Series B is the stress test for discovery calls. What worked at fifteen people fails at fifty unless the operating rhythm is deliberate.
The Series B move is to separate the model owner from the operators. One senior human owns strategy, discovery-to-opportunity conversion, and the weekly review; a small team runs the machine.
Add a second geography or segment only when the first one is producing a defensible number for two full quarters. Not before.
The binding constraint we see in healthcare and life sciences is almost always regulated-sale cycle length, not intent. Discovery calls is only useful in this vertical when it is pointed at that constraint — not at a generic growth number borrowed from another category.
Governance appears at Series B — that is fine, provided it accelerates rather than slows. The test is whether reviews still make decisions or just distribute updates.
The Series B failure mode of discovery calls is reading a script instead of running a diagnosis, amplified by headcount. Fix the root cause; do not paper over it with more people.
Compensation begins to matter now. Pay operators on discovery-to-opportunity conversion outcomes, not on effort. Effort-based comp at Series B produces theatre.
A well-run discovery calls function at Series B is the moat that survives to Series C. Companies that skip this discipline burn through raises trying to buy it back.
Concretely for healthcare and life sciences: the healthcare teams that install this get past procurement instead of dying in it. That is the reason it is worth installing discovery calls properly rather than half-heartedly across three vendors.
Frequently asked questions
Sales · healthcare — answered
- Does discovery calls work for healthcare and life sciences?
- Yes — provided it is aimed at regulated-sale cycle length, not intent rather than a generic growth number. The healthcare teams that install this get past procurement instead of dying in it.
- How does discovery calls change at Series B?
- Ownership separates from execution; operating rhythm gets more deliberate; governance appears.
- When should we expand to a second region?
- After the first region delivers two straight quarters of defensible discovery-to-opportunity conversion.
- What compensation model works for discovery calls operators at Series B?
- Outcome-linked on discovery-to-opportunity conversion, not activity-based.
- What is the Series B stress point?
- Reading a script instead of running a diagnosis, amplified by headcount. Fix the root, not the symptom.
- What is the healthcare specific pitfall with discovery calls?
- Running the generic playbook without adapting to healthcare buyers move under regulatory constraint and reward domain-specific messaging. The install has to be vertical-first.
Growth Broker editorial
Filed under sales · healthcare